This has been established through use of SRPK1 inhibiting compounds SRPN340 and Sphinx31 in a variety of tissues, including the kidney (Amin et al., 2011), retinal epithelium (Gammons et al., 2013; Batson et al., 2017), peripheral neurones (Hulse et al., 2014), prostate cancer (Mavrou and Oltean, 2016), and acute myeloid leukaemia (Tzelepis et al., 2018). Here, SRPK1 is linked to Familial prostate cancer.